

Table S1. Primer pairs and product sizes for gene transcripts.

Gene transcript*	Primer pair	Product size (bp)
B2M	Forward: 5'-ACTGAATTCACCCCACTGA-3' Reverse: 5'-CCTCCATGATGCTGCTTACA-3'	114
BST2 ¹	Forward: 5'-CACCTGCAACCACACTGT-3' Reverse: 5'-TTCTCAGTCGCTCCACCT-3'	149
CCL2 ²	Forward: 5'-AATCAATGCCCCAGTCACCTGC-3' Reverse: 5'-CGGAGTTTGGGTTTGCTTGTCC-3'	211
CXCL8 ³	Forward: 5'-GTGTGAAGGTGCAGTTTTGC-3' Reverse: 5'-TCTGCACCCAGTTTTCTTG-3'	203
DDX58 ⁴	Forward: 5'-GACTGGACGTGGCAAACAA-3' Reverse: 5'-TTGAATGCATCCAATATACTTCTG-3'	75
EIF2AK2 ⁵	Forward: 5'-GGAAAGCGAACAAGGAGTAAGG-3' Reverse: 5'-CCAAAGCGTAGAGGTCCACT-3'	97
FASLG	Forward: 5'-GGGTGGAAGTGGGGTGGCCTAT-3' Reverse: 5'-GGATTGGGCCTGGGGATGTTTCA-3'	126
GAPDH	Forward: 5'-AGCTGAACGGGAAGCTCACTGG-3' Reverse: 5'-GGAGTGGGTGTCGCTGTTGAAGTC-3'	209
IFIH1 ⁴	Forward: 5'-ACCAAATACAGGAGCCATGC-3' Reverse: 5'-CGTTCTTTGCGATTTCTTC-3'	205
IFIT1 ⁶	Forward: 5'-AGAAGCAGGCAATCACAGAAA-3' Reverse: 5'-CTGAAACCGACCATAGTGGAAT-3'	112

IFIT2 ⁶	Forward: 5'-CACATGGGCCGACTCTCAG-3' Reverse: 5'-CCACACTTTAACCGTGTCCAC-3'	134
IFIT3 ⁷	Forward: 5'-GAAGGAACTGGGCCGCTGCTAAG-3' Reverse: 5'-GCCCTGGCCCATTTCCTCACTACC-3'	103
IFITM1 ⁸	Forward: 5'-ACTCCGTGAAGTCTAGGGACA-3' Reverse: 5'-TGTCACAGAGCCGAATACCAG-3'	155
IFITM2 ⁸	Forward: 5'-ATCCCGGTAACCCGATCAC-3' Reverse: 5'-CTTCCTGTCCCTAGACTTCAC-3'	291
IFITM3 ⁸	Forward: 5'-GGTCTTCGCTGGACACCAT-3' Reverse: 5'-TGTCCTAGACTTCACGGAGTA-3'	276
IFN- α 1 ⁹	Forward: 5'-TCCATGAGCTGATCCAGCAGA-3' Reverse: 5'-ATTTCTGCTCTGACAACCTCCC-3'	274
IFN- α R1 ¹⁰	Forward: 5'-TTGTGTGAAAGCCAGAGCAC-3' Reverse: 5'-TCAAGAAGACTTTTCGCAGCA-3'	179
IFN- α R2 ¹⁰	Forward: 5'-CACCAGAGTTTGAGATTGTTGG-3' Reverse: 5'-GCTTGCTCATCACTGTGCTC-3'	250
IFN- β ¹¹	Forward: 5'-AAACTCATGAGCAGTCTGCA-3' Reverse: 5'-AGGAGATCTTCAGTTTCGGAGG-3'	168
IL1-RN ³	Forward: 5'-TCATGCTCTGTTCTTGGGAAT-3' Reverse: 5'-GCTTGTCTGCTTTCTGTTC-3'	131
IL-6 ¹²	Forward: 5'-ATGAACTCCTTCTCCACAAGCGC-3' Reverse: 5'-GAAGAGCCCTCAGGCTGGACTG-3'	628
IL-10 ¹³	Forward: 5'-GTGATGCCCAAGCTGAGA-3' Reverse: 5'-CACGGCCTTGCTCTTGTTTT-3'	138

ISG15 ¹⁴	Forward: 5'-GAGAGGCAGCGAACTCATCT-3' Reverse: 5'-AGCATCTTCACCGTCAGGTC-3'	99
ISG20 ¹⁵	Forward: 5'-CGCAGAGGCAGGCAGCAT-3' Reverse: 5'-CATGACCCACCACCAGCTT-3'	307
MIF ¹⁶	Forward: 5'-AGAACCGCTCCTACAGCAAG-3' Reverse: 5'-CCGCGTTCATGTCGTAATAG-3'	99
MX1 ¹⁷	Forward: 5'-ACAATCAGCCTGGTGGTGGTC-3' Reverse: 5'-CCTCCCCTACAGTTTCCTCTCC-3'	565
OAS1 ¹⁷	Forward: 5'-AGGTGGTAAAGGGTGGCT-3' Reverse: 5'-TGCTTGACTAGGCGGATG-3'	472
OAS2 ¹⁸	Forward: 5'-AACCTGGTTGACTTCTCCCAACCT-3' Reverse: 5'-TGTTGGGCTGGAGAACTCCTTGA-3'	131
OAS3 ¹⁸	Forward: 5'-GCTCAGTTCTGGCACCAACCAAA-3' Reverse: 5'-TTCATGAAGTTCCTCCGCAGCTCT-3'	114
PD-L1	Forward: 5'-ACGCATTTACTGTCACGGTTCC-3' Reverse: 5'-GACTTCGGCCTTGGGGTAGC-3'	446
PD-L2 ¹⁹	Forward: 5'-CAACTTGGCTGCTTCACATTTT-3' Reverse: 5'-TGTGGTGACAGGTCTTTTTGTTGT-3'	137
PEDF	Forward: 5'-CTTGACCGGAAGCATGAGTAT-3' Reverse: 5'-CCCTCAGTACGAAGATGAAAGG-3'	398
PGES3	Forward: 5'-GATTCACAAGACAGTGATGATG-3' Reverse: 5'-ATCAACTCAGGAATTCTCTCAA-3'	128
RSAD2 ²⁰	Forward: 5'-TGACGGAACAGATCAAAGCA-3' Reverse: 5'-GCACCAAGCAGGACACTTCT-3'	174

TBP ²¹	Forward: 5'-GCCTCCCCCAGCCCTTCTTT-3' Reverse: 5'-GCCACACCCTGCAACTCAACATCC-3'	106
TGF- β 2	Forward: 5'-GTACTACGCCAAGGAGGTTTAC-3' Reverse: 5'-TGTGGAGGTGCCATCAATAC-3'	568
TNF- α ¹²	Forward: 5'-TCTCGAACCCCGAGTGACAA-3' Reverse: 5'-TGAAGAGGACCTGGGAGTAG-3'	181
TSP1	Forward: 5'-AAAGGATAATTGCCCAACC-3' Reverse: 5'-CGGTCTCCCACATCATCTCT-3'	177
VEGFA	Forward: 5'-TGCTGTCTTGGGTGCATT-3' Reverse: 5'-GTGCTGTAGGAAGCTCATCTC-3'	365

*References for primers sequences sourced from the literature are provided below.

For primer pairs designed in-house, products were confirmed by sequencing.

B2M = β -2-microglobulin; BST2 = bone marrow stromal antigen 2;

DDX58 = DEXD/H-box helicase 58; EIF2AK2 = eukaryotic translation initiation factor

2-alpha kinase 2; FASLG = Fas ligand; GAPDH = glyceraldehyde-3-phosphate

dehydrogenase; IFIH1 = interferon induced with helicase C domain 1;

IFIT = interferon-induced protein with tetratricopeptide repeats; IFITM = interferon-

induced transmembrane protein; IFN = interferon; IL = interleukin; ISG = interferon-

stimulated gene; MIF = macrophage migration inhibitory factor; MX1 = MX dynamin-

like GTPase 1; OAS = 2'-5'-oligoadenylate synthetase; PD-L = programmed cell

death ligand; PEDF = pigment epithelium-derived factor; PGES3 = prostaglandin E

synthase 3; TBP = TATA-binding protein; TGF- β 2 = transforming growth factor β 2;

TNF- α = tumor necrosis factor α ; TSP1 = thrombospondin 1; VEGFA = vascular

endothelial growth factor A; RSAD2 = radical SAM domain-containing 2.

References

1. Guzzo C, Jung M, Graveline A, Banfield BW, Gee K. IL-27 increases BST-2 expression in human monocytes and T cells independently of type I IFN. *Scientific Rep.* 2012;2:974.
2. Nio-Kobayashi J, Kudo M, Sakuragi N, Kimura S, Iwanaga T, Duncan WC. Regulated C-C motif ligand 2 (CCL2) in luteal cells contributes to macrophage infiltration into the human corpus luteum during luteolysis. *Mol Hum Reprod.* 2015;21:645-654.
3. Blengio F, Raggi F, Pierobon D, et al. The hypoxic environment reprograms the cytokine/chemokine expression profile of human mature dendritic cells. *Immunobiology.* 2013;218:76-89.
4. Reins RY, Baidouri H, McDermott AM. Vitamin D Activation and Function in Human Corneal Epithelial Cells During TLR-Induced Inflammation. *Invest Ophthalmol Vis Sci* 2015;56:7715-7727.
5. Hu CW, Yin GF, Wang XR, et al. IL-24 Induces Apoptosis via Upregulation of RNA-Activated Protein Kinase and Enhances Temozolomide-Induced Apoptosis in Glioma Cells. *Oncol Res.* 2014;22:159-165.
6. Sharma N, Verma R, Kumawat KL, Basu A, Singh SK. miR-146a suppresses cellular immune response during Japanese encephalitis virus JaOArS982 strain infection in human microglial cells. *J Neuroinflammation.* 2015;12:30.
7. Niess H, Camaj P, Mair R, et al. Overexpression of IFN-induced protein with tetratricopeptide repeats 3 (IFIT3) in pancreatic cancer: cellular "pseudoinflammation" contributing to an aggressive phenotype. *Oncotarget.* 2015;6:3306-3318.

8. Warren CJ, Griffin LM, Little AS, Huang IC, Farzan M, Pyeon D. The antiviral restriction factors IFITM1, 2 and 3 do not inhibit infection of human papillomavirus, cytomegalovirus and adenovirus. *PLoS one*. 2014;9:e96579.
9. Harper MS, Guo K, Gibbert K, et al. Interferon-alpha Subtypes in an Ex Vivo Model of Acute HIV-1 Infection: Expression, Potency and Effector Mechanisms. *PLoS Pathog*. 2015;11:e1005254.
10. Farmer JR, Altschaeffl KM, O'Shea KS, Miller DJ. Activation of the type I interferon pathway is enhanced in response to human neuronal differentiation. *PLoS one*. 2013;8:e58813.
11. Herdy B, Karonitsch T, Vladimer GI, et al. The RNA-binding protein HuR/ELAVL1 regulates IFN-beta mRNA abundance and the type I IFN response. *Eur J Immunol*. 2015;45:1500-1511.
12. Jang CH, Choi JH, Byun MS, Jue DM. Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. *Rheumatology*. 2006;45:703-710.
13. Wilkinson J, Radkowski M, Eschbacher JM, Laskus T. Activation of brain macrophages/microglia cells in hepatitis C infection. *Gut*. 2010;59:1394-1400.
14. Muscat P, Mercado K, Payne K, Chahal H, Jones G. PHF11 expression and cellular distribution is regulated by the Toll-Like Receptor 3 Ligand Polyinosinic:Polycytidylic Acid in HaCaT keratinocytes. *BMC Immunol*. 2015;16:69.
15. Vestergaard AL, Knudsen UB, Munk T, Rosbach H, Martensen PM. Transcriptional expression of type-I interferon response genes and stability of housekeeping genes in the human endometrium and endometriosis. *Mol Hum Reprod*. 2011;17:243-254.

16. Giannice R, Erreni M, Allavena P, Buscaglia M, Tozzi R. Chemokines mRNA expression in relation to the Macrophage Migration Inhibitory Factor (MIF) mRNA and Vascular Endothelial Growth Factor (VEGF) mRNA expression in the microenvironment of endometrial cancer tissue and normal endometrium: a pilot study. *Cytokine*. 2013;64:509-515.
17. Wang B, Zhao XP, Fan YC, Zhang JJ, Zhao J, Wang K. IL-17A but not IL-22 suppresses the replication of hepatitis B virus mediated by over-expression of MxA and OAS mRNA in the HepG2.2.15 cell line. *Antiviral Res*. 2013;97:285-292.
18. Kwon YC, Kang JI, Hwang SB, Ahn BY. The ribonuclease L-dependent antiviral roles of human 2',5'-oligoadenylate synthetase family members against hepatitis C virus. *FEBS Lett*. 2013;587:156-164.
19. Hobo W, Maas F, Adisty N, et al. siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells. *Blood*. 2010;116:4501-4511.
20. Wang B, Fang Y, Wu Y, et al. Viperin is induced following toll-like receptor 3 (TLR3) ligation and has a virus-responsive function in human trophoblast cells. *Placenta*. 2015;36:667-673.
21. Wu C, Wang X, Zhong M, et al. Evaluation of potential reference genes for qRT-PCR studies in human hepatoma cell lines treated with TNF-alpha. *Acta Biochim Biophys Sin (Shanghai)*. 2013;45:780-786.